Search research articles
Contact Us
Filters
Showing results (31-40 of 46) with videos related to
Page
of 5
Sort By:
British Journal of Cancer
|
May 14, 2022
A first-in-human Phase I dose-escalation trial of the novel therapeutic peptide, ALM201, demonstrates a favourable safety profile in unselected patients with ovarian cancer and other advanced solid tumours
Aya El Helali, Ruth Plummer, Gordon C Jayson, et al.
British Journal of Cancer
|
March 23, 2016
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer
Yvette Drew, Jonathan Ledermann, Geoff Hall, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 29, 2009
Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma
Rachel A Daniel, Agata L Rozanska, Huw D Thomas, et al.
Investigational New Drugs
|
June 13, 2012
Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors
Christophe Massard, Jane Margetts, Nadia Amellal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 27, 2024
Targeted and Shallow Whole-Genome Sequencing Identifies Therapeutic Opportunities in p53abn Endometrial Cancers
Amy Jamieson, Juliana Sobral de Barros, Dawn R Cochrane, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
November 6, 2019
Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, <i>BRCA</i>-mutated, high-grade ovarian cancer, and an update on safety
Rebecca S Kristeleit, Ana Oaknin, Isabelle Ray-Coquard, et al.
Clinical Lung Cancer
|
June 21, 2022
Safety and Efficacy of Dostarlimab in Patients With Recurrent/Advanced Non-small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial
Victor Moreno, Desamparados Roda, Joanna Pikiel, et al.
British Journal of Cancer
|
December 9, 2022
Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10
Rebecca S Kristeleit, Yvette Drew, Amit M Oza, et al.
Blood Advances
|
May 24, 2018
Inhibition of ATR acutely sensitizes acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase
Sarah E Fordham, Helen J Blair, Claire J Elstob, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 8, 2017
A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline <i>BRCA1/2</i>-Mutated Ovarian Carcinoma or Other Solid Tumors
Rebecca Kristeleit, Geoffrey I Shapiro, Howard A Burris, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 46) with videos related to
Sort By:
Page
of 5
British Journal of Cancer
|
May 14, 2022
A first-in-human Phase I dose-escalation trial of the novel therapeutic peptide, ALM201, demonstrates a favourable safety profile in unselected patients with ovarian cancer and other advanced solid tumours
Aya El Helali, Ruth Plummer, Gordon C Jayson, et al.
British Journal of Cancer
|
March 23, 2016
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer
Yvette Drew, Jonathan Ledermann, Geoff Hall, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 29, 2009
Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma
Rachel A Daniel, Agata L Rozanska, Huw D Thomas, et al.
Investigational New Drugs
|
June 13, 2012
Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors
Christophe Massard, Jane Margetts, Nadia Amellal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 27, 2024
Targeted and Shallow Whole-Genome Sequencing Identifies Therapeutic Opportunities in p53abn Endometrial Cancers
Amy Jamieson, Juliana Sobral de Barros, Dawn R Cochrane, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
November 6, 2019
Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, <i>BRCA</i>-mutated, high-grade ovarian cancer, and an update on safety
Rebecca S Kristeleit, Ana Oaknin, Isabelle Ray-Coquard, et al.
Clinical Lung Cancer
|
June 21, 2022
Safety and Efficacy of Dostarlimab in Patients With Recurrent/Advanced Non-small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial
Victor Moreno, Desamparados Roda, Joanna Pikiel, et al.
British Journal of Cancer
|
December 9, 2022
Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10
Rebecca S Kristeleit, Yvette Drew, Amit M Oza, et al.
Blood Advances
|
May 24, 2018
Inhibition of ATR acutely sensitizes acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase
Sarah E Fordham, Helen J Blair, Claire J Elstob, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 8, 2017
A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline <i>BRCA1/2</i>-Mutated Ovarian Carcinoma or Other Solid Tumors
Rebecca Kristeleit, Geoffrey I Shapiro, Howard A Burris, et al.
Page
of 5